Management of Hepatitis B Patients in Dialysis Units

Screening and Diagnosis

All patients should undergo comprehensive HBV screening before admission to a dialysis unit with tests for HBsAg, anti-HBs, and anti-HBc, as recommended by the American Journal of Kidney Diseases 1
Patients susceptible to HBV infection should be screened monthly for HBsAg to identify seroconversion early, according to the American Journal of Kidney Diseases 1
Patients immune to HBV should have antibody levels checked annually and be revaccinated if levels decrease below 10 IU/L, as suggested by the American Journal of Kidney Diseases 1
Patients should also be screened for HCV and HIV infections as part of comprehensive blood-borne pathogen management, recommended by the American Journal of Kidney Diseases 1

Strict adherence to standard infection control procedures is essential to prevent transmission of blood-borne pathogens, as emphasized by the American Journal of Kidney Diseases 2, 3
Key infection control practices include proper hand hygiene and glove changes between patient contacts, aseptic medication preparation and administration, thorough cleaning and disinfection of dialysis stations and high-touch surfaces, and adequate separation of clean supplies from contaminated materials, all recommended by the American Journal of Kidney Diseases 2
Regular observational audits of infection control procedures should be conducted, as suggested by the American Journal of Kidney Diseases 2
Dialyzers of HBV-infected patients can be reused if standard infection control procedures are followed, according to the American Journal of Kidney Diseases 2

Vaccination is necessary for all dialysis patients without anti-HBs protection, as recommended by the Clinical and Molecular Hepatology 4, 5
Vaccination efficacy is higher with earlier administration, as antibody production rates are lower in dialysis patients compared to the general population, according to the Clinical and Molecular Hepatology 5
Antibody response decreases as residual renal function declines, as noted by the Clinical and Molecular Hepatology 5
Booster vaccination is needed if annual testing reveals anti-HBs levels below 10 mIU/L in dialysis patients, recommended by the Clinical and Molecular Hepatology 6

Oral antiviral agents are recommended rather than interferon for HBV-infected dialysis patients due to increased adverse events, as suggested by the Clinical and Molecular Hepatology 4, 5
Entecavir and tenofovir are preferred first-line agents based on their potency and resistance profiles, with dose adjustments according to residual renal function, recommended by the Clinical and Molecular Hepatology 4, 5
Lamivudine has shown effectiveness in small studies but has high resistance rates, according to the Clinical and Molecular Hepatology 5
Adefovir requires careful dose adjustment due to potential nephrotoxicity in patients with residual renal function, as noted by the Clinical and Molecular Hepatology 5

Regular monitoring of HBV DNA levels is essential during and after antiviral therapy, as recommended by the Clinical and Molecular Hepatology 5
Dialysis centers should track all HBV test results to identify new cases of infection, suggested by the American Journal of Kidney Diseases 2

For HBV/HCV co-infected patients, determine which virus is dominant through serologic or virologic tests, as recommended by the Clinical and Molecular Hepatology 5
All patients with HBV should undergo testing for HCV infection prior to antiviral therapy, suggested by the Kidney International 7, 8
If HBsAg is absent but markers of prior HBV infection are detected, monitor for HBV reactivation with HBV DNA testing if liver function tests rise, recommended by the Kidney International 7, 8
Kidney transplantation should be considered as the best therapeutic option for patients with chronic kidney disease regardless of HBV infection status, as suggested by the Kidney International 7
Patients with HBV should be evaluated for severity of liver disease and presence of portal hypertension prior to kidney transplantation, recommended by the Kidney International 7

When a new case of HBV is identified, aggressive measures must be taken to improve hand hygiene, injection safety, and environmental cleaning, as recommended by the American Journal of Kidney Diseases 2